Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease

  • Niels Vande Casteele
  • Jun Oyamada
  • Chisato Shimizu
  • Brookie M. Best
  • Edmund V. Capparelli
  • Adriana H. Tremoulet
  • Jane C. Burns
Original Research Article

Abstract

Background

Infliximab, a monoclonal antibody directed against tumor necrosis factor-α, is being evaluated as adjunctive therapy to intravenous immunoglobulin (IVIG) for treatment of young children with acute Kawasaki disease (KD).

Objective

The aim of this study was to develop a population pharmacokinetic (PopPK) model for infliximab in children with KD, and to evaluate the impact of covariates on infliximab disposition. Specifically, we wanted to investigate the effect of body weight and IVIG administration on PK parameters.

Methods

In the current PopPK analysis, 70 subjects with a median (interquartile range) age of 2.9 years (1.3–4.4) were included from two randomized controlled trials. Infliximab concentration–time data were best described by a two-compartment model with first-order elimination using non-linear mixed-effects modeling (NONMEM 7.3).

Results

The clearance, volume of distribution of the central (V1) and peripheral (V2) compartment, and intercompartmental clearance estimates (95% confidence interval) from the PopPK analysis were 0.117 (0.091–0.134) L/day, 0.801 (0.545–0.960) L, 0.962 (0.733–1.759) L, and 0.692 (0.482–1.779) L/day, respectively. Allometric body weight was included on all parameters of the structural model and a covariate analysis revealed that administering infliximab after IVIG, as opposed to before, resulted in a 50% decrease in V2.

Conclusions

Our study shows that the timing of infliximab administration relative to IVIG administration affects the disposition of the monoclonal antibody. These results may have important implications for other monoclonal antibodies administered in combination with IVIG for treating inflammatory diseases.

Notes

Acknowledgements

The authors thank Joan Pancheri, RN, for clinical sample collection, DeeAnna Scherrer for technical assistance, and Emelia Bainto and Nipha Sivilay for database development.

Author contributions

NVC wrote the manuscript; NVC, AHT, and JCB designed the research; NVC, JO, CS, AHT, and JCB performed the research; NVC, JO, CS, BMB, EVC, AHT, and JCB analyzed the data; and JO, CS, BMB, EVC, AHT, and JCB critically revised the manuscript for important intellectual content. All authors approved the final version of the article, including the authorship list.

Compliance with Ethical Standards

Funding

No funding was received for any part of the development and publication of the manuscript. The study by Burns et al. was supported by a grant from Centocor, Inc. and the National Institute for Child Health and Human Development, Pediatric Pharmacology Research Unit (PPRU) Network (5U10HD031318). Centocor Inc. performed the determinations of infliximab levels and the assays for anti-infliximab antibodies. The study by Tremoulet et al. was supported in part by an FDA Orphan Drug grant (FD 003514) awarded to JCB, and a Robert Wood Johnson Foundation grant awarded to AHT. Janssen Biotech, the manufacturer of infliximab, provided commercial-grade drug for this study.

Conflict of interest

Niels Vande Casteele has received consultancy fees from Janssen outside of the submitted work. Jun Oyamada, Chisato Shimizu, Brookie M. Best, Edmund V. Capparelli, Adriana H. Tremoulet, and Jane C. Burns have no conflicts of interest to declare.

Supplementary material

40262_2018_653_MOESM1_ESM.docx (161 kb)
Supplementary material 1 (DOCX 160 kb)

References

  1. 1.
    Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153(1):117–21.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48(2):247–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56(1):29–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644.e1–649.e1.CrossRefGoogle Scholar
  8. 8.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122(2):146–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68.CrossRefPubMedGoogle Scholar
  12. 12.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Vande Casteele N, Buurman DJ, Sturkenboom MGG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36(8):765–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Van Stappen T, Brouwers E, Tops S, Geukens N, Vermeire S, Declerck PJ, et al. Generation of a highly specific monoclonal anti-infliximab antibody for harmonization of TNF-coated infliximab assays. Ther Drug Monit. 2015;37(4):479–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Marini JC, Sendecki J, Cornillie F, Popp JW Jr, Black S, Blank M, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of remicade(R). AAPS J. 2017;19(1):161–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol. 1994;152(7):3550–8.PubMedGoogle Scholar
  17. 17.
    Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.CrossRefPubMedGoogle Scholar
  18. 18.
    Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.CrossRefPubMedGoogle Scholar
  19. 19.
    Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12(1):1–13.CrossRefPubMedGoogle Scholar
  20. 20.
    Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108(6):962–71.CrossRefPubMedGoogle Scholar
  21. 21.
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet.  https://doi.org/10.1007/s40262-017-0627-0 (Epub 12 Jan 2018).
  23. 23.
    Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64(10):1539–45.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineUniversity of California San DiegoLa JollaUSA
  2. 2.Department of PediatricsUniversity of California San DiegoLa JollaUSA

Personalised recommendations